NASDAQ:GTXI GTX Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GTx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.66 +0.12 (+4.72 %) (As of 12/4/2020 12:00 AM ET) Add Compare Share Today's Range$2.57Now: $2.66▼$2.7450-Day Range$1.20MA: $4.77▼$7.2052-Week Range$0.74Now: $2.66▼$25.60Volume633,711 shsAverage Volume390,540 shsMarket Capitalization$63.97 millionP/E RatioN/ADividend YieldN/ABeta2.22 ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for GTX. Previous Next 2.9 Community Rank Outperform VotesGTX has received 315 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGTX has received 227 “underperform” votes. (Add your “underperform” vote.)Community SentimentGTX has received 58.12% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote “Outperform” if you believe GTXI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGTX does not currently pay a dividend.Dividend GrowthGTX does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GTX insiders have not sold or bought any company stock.Percentage Held by Insiders40.90% of the stock of GTX is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.50% of the stock of GTX is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GTX are expected to decrease in the coming year, from ($0.97) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GTX is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GTX is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGTX has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.75 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GTXI Previous Symbol CUSIP40052B10 CIK1260990 Webwww.gtxinc.com Phone901-523-9700Employees21 Debt Debt-to-Equity RatioN/A Current Ratio12.39 Quick Ratio12.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book2.44Profitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-38,420,000.00 Net MarginsN/A Return on Equity-104.19% Return on Assets-86.42%Miscellaneous Outstanding Shares24,050,000Market Cap$63.97 million Next Earnings DateN/A OptionableOptionable Receive GTXI News and Ratings via Email Sign-up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter. GTX (NASDAQ:GTXI) Frequently Asked Questions What stocks does MarketBeat like better than GTX? Wall Street analysts have given GTX a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GTX wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were GTX's earnings last quarter? GTx, Inc. (NASDAQ:GTXI) released its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.09. View GTX's earnings history. Who are some of GTX's key competitors? Some companies that are related to GTX include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of GTX own? Based on aggregate information from My MarketBeat watchlists, some companies that other GTX investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL) and Amarin (AMRN). Who are GTX's key executives? GTX's management team includes the following people: Dr. Robert James Wills B.S., M.S., Ph.D., Exec. Chairman (Age 65)Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 56)Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 70)Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 44)Dr. Diane C. Young, VP & Chief Medical Officer (Age 62) What is GTX's stock symbol? GTX trades on the NASDAQ under the ticker symbol "GTXI." What is GTX's stock price today? One share of GTXI stock can currently be purchased for approximately $2.66. How big of a company is GTX? GTX has a market capitalization of $63.97 million. The biopharmaceutical company earns $-38,420,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. GTX employs 21 workers across the globe. What is GTX's official website? The official website for GTX is www.gtxinc.com. How can I contact GTX? GTX's mailing address is 17 W Pontotoc Ave. Suite 100, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected] This page was last updated on 12/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
